Clinical Trial Update: Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients [Phase 3]

View source ↗

Summary

Phase 3 trial assessing the safety and efficacy of aliskiren in slowing atherosclerosis progression in patients with coronary artery disease; results have been …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Artery Disease
• Coronary Atherosclerosis

Drugs mentioned

• Aliskiren (Aliskiren)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Coronary Artery Disease (CAD), Coronary Atherosclerosis | Phase 3 | Status: COMPLETED | Results posted: 2014-05-07